Merck lines up for a quick approval with its C. diff therapy

Damian Garde

is nearing FDA for its Clostridium difficile-fighting antibody, picking up the agency's priority review designation with the promise of a shortened vetting process.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS